Pharma companies that used large field forces for multiple divisions, selling the same me-too products to create a resounding Share-of-the-Voice in the market are beginning to Stare-at-the-Diminishing-Returns for investments on traditional sales and marketing strategies, if they can be called strategies at all in the first place. Most pharma companies and professionals like Black & Yellow cabs, continue to hope against hope, that somehow they will be able to continue to hold on to their businesses and jobs till their shares are sold and EMIs are paid. After that, who cares? The answer to pharma and healthcare’s challenges will need a combination of profound domain knowledge and experience combined with digital skills to engage Rx customers meaningfully.

IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars

India's pharmaceutical market charged into 2026 with strong momentum,...

Digistorm

DigiStorm 2017 special report and photo montage inside

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Marketing

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Policies/Sales

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Strategy

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Draft Pharma Policy

Get an in-depth view into the Draft Pharma Policy - MedicinMan does a deep dive with the President of Karnataka Drug and Pharmaceutical Manufacturers Association

72nd Republic Day: What’s the Road Ahead for Indian Pharma?

“We are getting too happy, for too little”: these...

Frontline Managers

Articles by Vivek Hattangadi, Raja Reddy, K. Hariram, Satish Kota, P. S. Parameswaran, Gopal Kishore, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal and Mahendra Kumar Rai

The ‘Amazonization’ of Healthcare

Inside this Issue 1. The 'Amazonization' of Healthcare by Salil Kallianpur Amazon's drive...

Crafting a Digital Strategy: The Roadmap for 2021

In many situations, technology upgradation is often construed as digital transformation. In a recently conducted survey by Altimeter, 88% of companies said that they were undergoing ‘digital transformation’ but only 25% said that they did so with the purpose beyond investing in new technology. The real definition of digital transformation is the realignment of, or new investment in technology, business models, and processes to create value for customers in a dynamic digital economy.